| No. Pts | No. USP39 | p Value | |
---|---|---|---|---|
Low | High | |||
Overall: n (%) | 176 (100.0) | 88 (50.0) | 88 (50.0) | 0.286a |
 Male | 101 (57.4) | 47 (26.7) | 54 (30.7) | |
 Female | 75 (42.6) | 41 (23.3) | 34 (19.3) | |
Mean patient age, y (range) | 65.2 (34–85) | 63.7(42–85) | 66.6 (34–85) | < 0.000b |
WHO performance status: n (%) | Â | Â | Â | 0.146a |
 0 | 65 (36.9) | 29 (16.5) | 36 (20.5) | |
 1 | 63 (35.8) | 35 (19.9) | 28 (15.9) | |
 2 | 37 (21.0) | 16 (9.1) | 21 (11.9) | |
 3 | 10 (5.7) | 8 (4.5) | 2 (1.1) | |
 4 | 1 (0.6) | 0 (0.0) | 1 (0.6) | |
TNM stage: n (%) | Â | Â | Â | 0.919a |
 I | 49 (27.8) | 25 (14.2) | 24 (13.6) | |
 II | 29 (16.5) | 16 (9.1) | 13 (7.4) | |
 III | 40 (22.7) | 19 (10.8) | 21 (11.9) | |
 IV | 58 (33.0) | 28 (15.9) | 30 (17.0) | |
Fuhrman grade: n (%) | Â | Â | Â | 0.726a |
 1 | 9 (5.1) | 6 (3.4) | 3 (1.7) | |
 2 | 34 (19.3) | 18 (10.2) | 16 (9.1) | |
 3 | 93 (52.8) | 45 (25.6) | 48 (27.3) | |
 4 | 40 (22.7) | 19 (10.8) | 21 (11.9) | |
Patient outcome: n (%) | Â | Â | Â | 0.008a |
 Died | 111 (63.1) | 47 (21.6) | 64 (27.3) | |
 Alive | 65 (36.9) | 41 (4.0) | 24 (1.1) | |
Median OS, mo (95% CI) | 39 (33.4–44.6) | 59 (14.1–103.9) | 35 (23.0–47.0) | 0.006c |